Sandu Pharmaceuticals Intrinsic Value
Sandu Pharmaceuticals (SANDUPHQ) median intrinsic value is ₹35.85 from 8 valuation models (range ₹12–₹84), vs current price ₹41.59 — -13.8% downside (Trading Above Median Value), margin of safety -16.0%. For current market price and key ratios, visit Sandu Pharmaceuticals share price chart.
SANDUPHQ Valuation Methods Summary — DCF, Graham Number & P/E
Sandu Pharmaceuticals intrinsic value across 8 models vs current price ₹41.59 — upside/downside and value range per method. Analyse SANDUPHQ shareholder distribution to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹29.92 | ₹23.94 - ₹35.90 | -28.1% | EPS: ₹1.36, Sector P/E: 22x |
| Book Value Method | asset | ₹84.00 | ₹75.60 - ₹92.40 | +102.0% | Book Value/Share: ₹42.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹83.18 | ₹74.86 - ₹91.50 | +100.0% | Revenue/Share: ₹56.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹40.00 | ₹36.00 - ₹44.00 | -3.8% | EBITDA: ₹4.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹16.64 | ₹13.31 - ₹19.97 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹12.48 | ₹11.23 - ₹13.73 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹21.01 | ₹18.91 - ₹23.11 | -49.5% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹35.85 | ₹32.27 - ₹39.44 | -13.8% | EPS: ₹1.36, BVPS: ₹42.00 |
SANDUPHQ Intrinsic Value vs Market Price — All Valuation Models
Sandu Pharmaceuticals fair value range ₹12–₹84 vs current market price ₹41.59 across 8 valuation models. Read SANDUPHQ ex-dividend dates for the complete payout history and dividend yield track record.
SANDUPHQ Intrinsic Value Analysis — Undervalued or Overvalued?
Sandu Pharmaceuticals median intrinsic value ₹35.85, current price ₹41.59 — Trading Above Median Value by 13.8%, margin of safety -16.0%.
What is the intrinsic value of SANDUPHQ?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Sandu Pharmaceuticals (SANDUPHQ) is ₹35.85 (median value). With the current market price of ₹41.59, this represents a -13.8% variance from our estimated fair value.
The valuation range spans from ₹12.48 to ₹84.00, indicating ₹12.48 - ₹84.00.
Is SANDUPHQ undervalued or overvalued?
Based on our multi-method analysis, Sandu Pharmaceuticals (SANDUPHQ) appears to be trading above median value by approximately 13.8%.
SANDUPHQ Financial Health — Key Ratios vs Industry Benchmarks
Sandu Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 13.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Operating Margin | 3.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.00x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
SANDUPHQ Cash Flow Quality — Operating & Free Cash Flow
Sandu Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |